Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 819.61M |
| Revenue (ttm) | 9.02M |
| Net Income (ttm) | -118.72M |
| Shares Out | 26.32M |
| EPS (ttm) | -5.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $31.14 |
| Previous Close | $31.22 |
| Change ($) | -0.08 |
| Change (%) | -0.26% |
| Day's Open | 31.14 |
| Day's Range | 30.84 - 32.43 |
| Day's Volume | 294,115 |
| 52-Week Range | 24.87 - 129.71 |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
SAN DIEGO, Calif.--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...
SAN DIEGO, June 2, 2021 /PRNewswire/ -- Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic production systems for nucleic acids, today announced granting Arcturus Thera...
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -85.34% and -27.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 220.90% over the past year to ($2.15), wh...
SAN DIEGO,--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
Probably not, but at least one of them could make you thousands over time.
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrials--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 64.47% over the past year to ($1.25), whi...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021
With the trading day more than halfway over, the broad markets were trading mixed.
Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BioCEO--Arcturus Therapeutics to Present at Upcoming Investor Conferences
Stocks without sturdy fundamentals are toxic for your portfolio. Identifying such bloated stocks accurately and dumping them at the right time can protect your returns.
Probably not, if you're investing for the long term.
Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
ARCT peaked and then slumped in recent weeks as investors lost interest in its coronavirus vaccine. Promising platform and advantages suggests this is a worthwhile holding.
With the trading day about half over, the broad markets were pushing higher on Tuesday The S&P 500 and Dow Jones industrial average were both up fractionally, and the Nasdaq posted the largest gain, clo...
Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.
One Wall Street analyst is very bullish about the biotech's prospects.
Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicines company ...
The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BiotechShowcase--Arcturus Therapeutics to Present at Upcoming Investor Conference
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.
Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical tri...
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Investors in fast-moving biotechs made out like bandits.
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
Two top performers fell back to earth on Tuesday.
Investors obviously considered these to be underwhelming, however.
Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Arctur...
The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.
An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, California-based...
Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Preclinical Data
One's a healthcare giant. The other is a small clinical-stage biotech.
An analyst downgraded the biotech stock.
Nothing compares to these companies.
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
They each have a key competitive edge that could set them apart.
About ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issue... [Read more...]
| Industry Biotechnology | Founded 2013 |
| Stock Exchange NASDAQ | Ticker Symbol ARCT |
Financial Performance
In 2020, ARCT's revenue was $9.54 million, a decrease of -54.12% compared to the previous year's $20.79 million. Losses were -$72.15 million, 177.6% more than in 2019.
Analyst Forecasts
According to 13 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 80.36, which is an increase of 158.06% from the latest price.